Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) and Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.
Profitability
This table compares Tectonic Therapeutic and Fresh Tracks Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tectonic Therapeutic | N/A | -35.53% | -31.97% |
| Fresh Tracks Therapeutics | N/A | N/A | N/A |
Earnings and Valuation
This table compares Tectonic Therapeutic and Fresh Tracks Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tectonic Therapeutic | N/A | N/A | $12.16 million | ($5.89) | -5.35 |
| Fresh Tracks Therapeutics | $8.01 million | 0.69 | -$5.69 million | ($1.41) | -0.66 |
Volatility & Risk
Tectonic Therapeutic has a beta of 2.62, meaning that its stock price is 162% more volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Tectonic Therapeutic and Fresh Tracks Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tectonic Therapeutic | 0 | 0 | 5 | 1 | 3.17 |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Tectonic Therapeutic currently has a consensus target price of $80.50, suggesting a potential upside of 155.64%. Given Tectonic Therapeutic’s stronger consensus rating and higher probable upside, research analysts clearly believe Tectonic Therapeutic is more favorable than Fresh Tracks Therapeutics.
Insider and Institutional Ownership
62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. 9.2% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 0.2% of Fresh Tracks Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Tectonic Therapeutic beats Fresh Tracks Therapeutics on 8 of the 13 factors compared between the two stocks.
About Tectonic Therapeutic
Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
About Fresh Tracks Therapeutics
Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
